PAVmed Inc. (PAVM)

Market Cap	46.30M
Revenue (ttm)	634,000
Net Income (ttm)	-90.33M
Shares Out	104.53M
EPS (ttm)	-0.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,470,564
Open	0.429
Previous Close	0.425
Day's Range	0.425 - 0.480
52-Week Range	0.350 - 2.340
Beta	0.85
Analysts	Buy
Price Target	1.50 (+238.68%)
Earnings Date	May 16, 2023

About PAVM

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo,...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 28, 2016
• Employees: 124
• Stock Exchange: NASDAQ
• Ticker Symbol: PAVM

Financial Performance

In 2022, PAVmed's revenue was $377,000, a decrease of -24.60% compared to the previous year's $500,000. Losses were -$89.26 million, 76.3% more than in 2021.

Analyst Forecast

According to 2 analysts, the average rating for PAVM stock is "Buy." The 12-month stock price forecast is $1.5, which is an increase of 238.68% from the latest price.

Price Target

$1.5

(238.68% upside)

Analyst Consensus: Buy